SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories - Quaterly Results

13 Nov 2024 Evaluate
The company witnessed a 9.01% growth in the revenue at Rs. 28719.70 millions for the quarter ended September 2024 as compared to Rs. 26345.90 millions during the year-ago period.Net profit stood at Rs. 6975.80  millions  compared to Rs. 6465.10 millions in the corresponding previous quarter,high by 7.90%.Operating profit surged to 8478.30 millions from the corresponding previous quarter of 7164.40 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 28719.70 26345.90 9.01 53720.70 48877.60 9.91 97477.20 90545.50 7.66
Other Income 1201.90 618.40 94.36 2262.90 1265.40 78.83 3059.90 2662.90 14.91
PBIDT 8478.30 7164.40 18.34 15745.60 11148.90 41.23 22711.20 16432.40 38.21
Interest 175.70 187.00 -6.04 390.10 401.20 -2.77 819.10 864.00 -5.20
PBDT 8302.60 6977.40 18.99 15355.50 10747.70 42.87 21253.80 15568.40 36.52
Depreciation 625.90 590.20 6.05 1269.40 1171.30 8.38 2443.50 2298.50 6.31
PBT 7676.70 6387.20 20.19 14086.10 9576.40 47.09 18810.30 13269.90 41.75
TAX 700.90 -77.90 -999.74 1277.80 396.90 221.95 1338.80 1925.20 -30.46
Deferred Tax -622.30 -1192.70 -47.82 -1158.00 -1257.20 -7.89 -1994.00 -350.00 469.71
PAT 6975.80 6465.10 7.90 12808.30 9179.50 39.53 17471.50 11344.70 54.01
Equity 239.10 239.10 0.00 239.10 239.10 0.00 239.10 239.10 0.00
PBIDTM(%) 29.52 27.19 8.56 29.31 22.81 28.50 23.30 18.15 28.38

Alkem Laboratories Share Price

5583.70 16.00 (0.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×